A major investor in Victoria’s Secret urged the flailing lingerie maker in a letter Tuesday to shake up its board – attacking the current chair as “over-tenured” with a “stale perspective.”BBRC International – which owns a nearly 13% stake in Victoria’s Secret, making it the second-largest shareholder – is calling for longtime Chair Donna James to be fired and asking for a board seat for its founder, Australian billionaire Brett Blundy. The private equity firm started building its stake in 2022 and has been ...

Core Insights - TG4050 demonstrates the ability to induce neoantigen-specific cytotoxic CD8+ T cell responses, which can target and eliminate tumor cells, potentially reducing the risk of cancer relapse [1][3][4] Company Overview - Transgene is a biotech company focused on developing virus-based immunotherapies for cancer treatment, with TG4050 being its lead asset [9][12] - TG4050 is an individualized therapeutic vaccine based on the myvac® platform, designed to stimulate the immune system to recognize and destroy tumor cells [10][12] Clinical Development - TG4050 is currently being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers, with the first immunogenicity data from the Phase II part expected in the second half of 2026 [14] - The trial includes a randomized study design, assessing the treatment benefits of TG4050 in patients at risk of relapse [14] Immunological Data - New immunological data presented at the SITC Annual Meeting confirm TG4050's mechanism of action and its potential for sustained prevention of cancer relapses [4][5] - CD8+ T cells induced by TG4050 exhibit an effector phenotype and persist for up to two years post-treatment, indicating long-term immune response capabilities [8][5] Collaboration and Technology - Transgene collaborates with NEC Corporation, leveraging NEC's AI-driven platform to enhance the development of individualized neoantigen therapeutic vaccines [5][12] - NEC's Neoantigen Prediction System utilizes advanced AI to identify and select the most immunogenic sequences for the vaccine [15][12]

PRESS RELEASE Global Bioenergies: postponement of the takeover offers review hearing to 24 November Evry, 04 November 2025 – 05:45 p.m: The hearing which was held yesterday at the Commercial Court of Evry concluded with the decision to postpone until 24 November 2025 the review of the offers to take over Global Bioenergies’ activities. The new deadline for submitting the offers has been set up on 12 November 2025. As a reminder, the company had initiated a pre-pack sale process on 03 June 2025 and the Evry ...

Nanterre, November 03rd, 2025 Disclosure of transactions in on shares from October 27th to October 31st,2025 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 17th, 2025, to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from October 27th to October 31st,2025: I - Aggregate presentation by day and by market Issu ...

Core Insights - Advanced Micro Devices (AMD) shares have more than doubled in value in 2025, with significant expectations surrounding its upcoming quarterly results [1][4] - Traders anticipate a potential stock movement of up to 7% in either direction following the earnings report, with current stock levels around $256 [2][7] - The company is expected to report record revenue driven by strong demand for its data center chips, with adjusted earnings per share projected at $1.16 and revenue at $8.76 billion, reflecting a 28% year-over-year increase [5][7] Market Expectations - A majority of Wall Street analysts maintain a bullish outlook on AMD, with many rating it as a "buy," despite the stock already exceeding their consensus target [4] - The optimism surrounding AMD's stock is largely attributed to recent AI deals, particularly a significant agreement with OpenAI [3][4] - Concerns about a potential AI bubble and rising expectations ahead of the earnings report may add pressure on AMD to deliver strong results [3] Stock Performance - AMD's stock has experienced substantial gains this year, primarily fueled by optimism from the OpenAI deal [4] - Recent market conditions have seen AMD shares decline by approximately 2% amid broader tech sector declines, influenced by worries about an AI bubble [5]

Core Insights - The deployment of the first intelligent humanoid robot, named Hoxo, in the nuclear sector represents a significant technological advancement for the industry [2][3] - This initiative aims to enhance industrial performance and safety by integrating robotics with human operations in challenging environments [4][5] Company Overview - Orano is a leading international operator in nuclear materials, focusing on innovative solutions to address global energy and health challenges, with a workforce of 18,000 employees [7] - Capgemini is an AI-powered global business and technology transformation partner, with nearly 60 years of experience and a workforce of 420,000 across more than 50 countries, reporting global revenues of €22.1 billion in 2024 [8] Technological Innovation - Hoxo is equipped with advanced AI and sensors for real-time perception, autonomous navigation, and interaction, designed to replicate human movements and assist teams in nuclear facilities [3][4] - The project combines robotics, AI, computer vision, and digital twins, redefining human-machine interaction in sensitive environments and pushing the boundaries of industrial automation [6]

French public limited company (société anonyme)with a share capital of €1,467,334,437.50Registered office : 1973, boulevard de la Défense92000 Nanterre – France552 037 806 RCS Nanterrewww.vinci.com DISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTSAS OF 31 OCTOBER 2025 Total number of shares586,933,775Theoretical number of voting rights (including treasury stock)586,933,775Number of voting rights (excluding treasury stock)558,394,791 This disclosure is on VINCI web ...

Paris, 04 November 2025, 5:45pm Solid Q3 2025 performance, driven by higher volumes and margins across core energy distribution activities, amid lower oil prices.Strong operational execution more than offset adverse EUR/USD effects, confirming the strength of Rubis’s diversified business model.Energy Distribution: sustained volume growth in Retail & Marketing (+6%), with LPG unit margin increase in Europe and strong momentum in bitumen. Support & Services revenue lower than Q3 2024 (-17%), mostly driven by ...

Banks have sought tweaks to the Reserve Bank of India’s draft acquisition finance guidelines, including higher exposure limits, permission to fund unlisted companies’ merger and acquisition (M&A) plans, and approval to finance corporates acquiring majority stakes in tranches rather than in a single go.“The regulator must consider allowing banks to finance acquisitions of well-run unlisted entities, as various small-size listed entities have seen governance issues in the past,” a senior banker said seeking a ...

I focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ...